Stock Events

Stock Events

Santen Pharmaceutical. 

$10.99
18
+$0+0% Friday 13:30

Statistics

Day High
10.99
Day Low
10.99
52W High
11.45
52W Low
8.88
Volume
2,000
Avg. Volume
0
Mkt Cap
3.76B
P/E Ratio
16.36
Dividend Yield
1.17%
Dividend
0.13

Upcoming

30
SEP
Dividend Ex
Estimated
 
27
NOV
Dividend Payment
Estimated
 
31
MAR 27
Dividend Ex
Estimated
 
30
SEP 27
Dividend Ex
Estimated
 
26
NOV 27
Dividend Payment
Estimated
 

Dividends

1.17%Dividend Yield
Mar 26
$0.12
Nov 25
$0.13
Jun 25
$0.13
Nov 24
$0.12
Jun 24
$0.11
10Y Growth
0.12%
5Y Growth
-1.76%
3Y Growth
2.81%
1Y Growth
-3.23%

Earnings

12MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
0.12
0.15
0.18
0.21
Expected EPS
0.205985480318
Actual EPS
N/A

Financials

11.96%Profit Margin
Profitable
2019
2020
2021
2022
2023
2024
4.05BRevenue
483.85MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SNPHF. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates in the pharmaceuticals sector, including eye care products through its Alcon division, directly competing with Santen's focus on ophthalmology.
Roche
RHHBY
Mkt Cap258.9B
Roche, through its subsidiary Genentech, offers ophthalmic drugs, competing in the same space as Santen Pharmaceutical in treatments for eye diseases.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for Eylea, an injection for certain eye conditions, directly competing with Santen's products in the ophthalmology market.
Bausch Health Companies
BHC
Mkt Cap2.62B
Bausch Health Companies, formerly Valeant Pharmaceuticals, has a significant presence in the eye health market through its Bausch + Lomb segment, making it a direct competitor to Santen.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie, after acquiring Allergan, has expanded its portfolio in eye care products, including treatments for dry eye and glaucoma, competing with Santen's offerings.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its Vision Care division, offers products for eye health, including contact lenses and surgical products, competing with Santen in the broader eye care market.
Pfizer
PFE
Mkt Cap140.15B
Pfizer has a range of treatments in the field of ophthalmology, including therapies for glaucoma and eye inflammation, making it a competitor to Santen.
Alcon
ALC
Mkt Cap36.88B
Alcon focuses on eye care products ranging from surgical devices to contact lenses, competing with Santen in the ophthalmic products market.
Merck
MRK
Mkt Cap214.76B
Merck & Co., although not primarily focused on eye care, has developed treatments for conditions like glaucoma, positioning it as a competitor in specific segments of the ophthalmology market.

About

Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Show more...
CEO
Mr. Takeshi Ito
Employees
3744
Country
JP
ISIN
JP3336000009

Listings

F
DE
SZD.F
TSE
JP
4536.TSE
OTC Link
US
SNPHY
OTC Link
US
SNPHF

0 Comments

Share your thoughts

FAQ

What is Santen Pharmaceutical. stock price today?▼
The current price of SNPHF is $10.99 USD — it has increased by +0% in the past 24 hours. Watch Santen Pharmaceutical. stock price performance more closely on the chart.
What is Santen Pharmaceutical. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Santen Pharmaceutical. stocks are traded under the ticker SNPHF.
Is Santen Pharmaceutical. stock price growing?▼
SNPHF stock has risen by +0% compared to the previous week, the month change is a -2.31% fall, over the last year Santen Pharmaceutical. has showed a +4.37% increase.
What is Santen Pharmaceutical. market cap?▼
Today Santen Pharmaceutical. has the market capitalization of 3.76B
When is the next Santen Pharmaceutical. earnings date?▼
Santen Pharmaceutical. is going to release the next earnings report on May 12, 2026.
What were Santen Pharmaceutical. earnings last quarter?▼
SNPHF earnings for the last quarter are 0.16 USD per share, whereas the estimation was 0.19 USD resulting in a -16.7% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Santen Pharmaceutical. revenue for the last year?▼
Santen Pharmaceutical. revenue for the last year amounts to 4.05B USD.
What is Santen Pharmaceutical. net income for the last year?▼
SNPHF net income for the last year is 483.85M USD.
Does Santen Pharmaceutical. pay dividends?▼
Yes, SNPHF dividends are paid semi-annual. The last dividend per share was 0.12 USD. As of today, Dividend Yield (FWD)% is 1.17%.
How many employees does Santen Pharmaceutical. have?▼
As of April 02, 2026, the company has 3,744 employees.
In which sector is Santen Pharmaceutical. located?▼
Santen Pharmaceutical. operates in the Health Care sector.
When did Santen Pharmaceutical. complete a stock split?▼
The last stock split for Santen Pharmaceutical. was on March 27, 2015 with a ratio of 5:1.
Where is Santen Pharmaceutical. headquartered?▼
Santen Pharmaceutical. is headquartered in Osaka, JP.